Liesl Bourdeaud'huy, Celine Jacobs, Ciel De Vriendt, Jo Van Dorpe, Dimitri Roels
{"title":"克唑替尼治疗结膜TFG::ROS1融合阳性炎性肌成纤维细胞瘤。","authors":"Liesl Bourdeaud'huy, Celine Jacobs, Ciel De Vriendt, Jo Van Dorpe, Dimitri Roels","doi":"10.1097/IOP.0000000000003035","DOIUrl":null,"url":null,"abstract":"<p><p>This case describes the clinical course and management of a conjunctival inflammatory myofibroblastic tumor with a transforming growth factor::ROS proto-oncogene 1 fusion in a 33-year-old woman presenting with a progressively enlarging subconjunctival mass. Diagnosis was confirmed by biopsy and RNA next-generation sequencing. Treatment with the tyrosine kinase inhibitor crizotinib led to complete tumor resolution; however, therapy was discontinued due to a sarcoid-like granulomatous reaction. Visual acuity remained stable at 20/20 throughout, and no recurrence was observed. This case highlights the diagnostic challenges of conjunctival inflammatory myofibroblastic tumor, the therapeutic potential of targeted kinase inhibition, and the critical role of genomic profiling in guiding personalized treatment for rare ocular tumors such as inflammatory myofibroblastic tumor.</p>","PeriodicalId":19588,"journal":{"name":"Ophthalmic Plastic and Reconstructive Surgery","volume":" ","pages":""},"PeriodicalIF":1.3000,"publicationDate":"2025-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Conjunctival TFG::ROS1 Fusion Positive Inflammatory Myofibroblastic Tumor Treated With Crizotinib.\",\"authors\":\"Liesl Bourdeaud'huy, Celine Jacobs, Ciel De Vriendt, Jo Van Dorpe, Dimitri Roels\",\"doi\":\"10.1097/IOP.0000000000003035\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>This case describes the clinical course and management of a conjunctival inflammatory myofibroblastic tumor with a transforming growth factor::ROS proto-oncogene 1 fusion in a 33-year-old woman presenting with a progressively enlarging subconjunctival mass. Diagnosis was confirmed by biopsy and RNA next-generation sequencing. Treatment with the tyrosine kinase inhibitor crizotinib led to complete tumor resolution; however, therapy was discontinued due to a sarcoid-like granulomatous reaction. Visual acuity remained stable at 20/20 throughout, and no recurrence was observed. This case highlights the diagnostic challenges of conjunctival inflammatory myofibroblastic tumor, the therapeutic potential of targeted kinase inhibition, and the critical role of genomic profiling in guiding personalized treatment for rare ocular tumors such as inflammatory myofibroblastic tumor.</p>\",\"PeriodicalId\":19588,\"journal\":{\"name\":\"Ophthalmic Plastic and Reconstructive Surgery\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":1.3000,\"publicationDate\":\"2025-09-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Ophthalmic Plastic and Reconstructive Surgery\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1097/IOP.0000000000003035\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"OPHTHALMOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ophthalmic Plastic and Reconstructive Surgery","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/IOP.0000000000003035","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
Conjunctival TFG::ROS1 Fusion Positive Inflammatory Myofibroblastic Tumor Treated With Crizotinib.
This case describes the clinical course and management of a conjunctival inflammatory myofibroblastic tumor with a transforming growth factor::ROS proto-oncogene 1 fusion in a 33-year-old woman presenting with a progressively enlarging subconjunctival mass. Diagnosis was confirmed by biopsy and RNA next-generation sequencing. Treatment with the tyrosine kinase inhibitor crizotinib led to complete tumor resolution; however, therapy was discontinued due to a sarcoid-like granulomatous reaction. Visual acuity remained stable at 20/20 throughout, and no recurrence was observed. This case highlights the diagnostic challenges of conjunctival inflammatory myofibroblastic tumor, the therapeutic potential of targeted kinase inhibition, and the critical role of genomic profiling in guiding personalized treatment for rare ocular tumors such as inflammatory myofibroblastic tumor.
期刊介绍:
Ophthalmic Plastic and Reconstructive Surgery features original articles and reviews on topics such as ptosis, eyelid reconstruction, orbital diagnosis and surgery, lacrimal problems, and eyelid malposition. Update reports on diagnostic techniques, surgical equipment and instrumentation, and medical therapies are included, as well as detailed analyses of recent research findings and their clinical applications.